Addex Therapeutics AI Stock Analysis
Want to see CH:ADXN full AI Analyst Report?
Addex Therapeutics (ADXN) AI Stock Analysis
Addex Therapeutics
(Six Swiss:ADXN)
The overall score of 41 reflects a company in a precarious financial position with a weak stock price trend, partially offset by a moderately positive strategic outlook from its latest earnings call. The most significant factors are the severe financial distress, evidenced by a 97% revenue collapse and continuous cash burn, and a bearish technical profile with the stock trading below all major moving averages. The earnings call provides a glimmer of hope with an extended cash runway and a promising pipeline, but the immediate need for further financing and a dwindling cash balance remain critical risks.
Addex Therapeutics (ADXN) vs. iShares MSCI Switzerland ETF (EWL)
- Market Cap
- CHF 3.03M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.37M
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 0.81
- Revenue Growth
- -50.34%
- EPS Growth
- 4.75%
- Country
- Switzerland
- Employees
- 3
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Addex Therapeutics Business Overview & Revenue Model
Company Description
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Base...
Addex Therapeutics Earnings Call Summary
The call was predominantly positive, with management highlighting $2.8 million of financing, a cash runway into Q4 2027, regained rights to the GABAB PAM platform, strong preclinical chronic cough data, and continued progress across the Neurosterix and Addex pipelines. Offsetting factors included the CHF 0.8 million half-year cash balance, CHF 1.2 million of operating cash usage, continued net losses, an increase in Addex's share of Neurosterix's loss, and the need to secure financing before starting chronic cough IND-enabling studies.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Addex said it has $2.8 million raised through its ATM facility and now has a cash runway through into Q4 of 2027; it expects NTX-253 to complete phase I very soon and expects phase I data from the NTX-253 program in Q4 this year, while NTX-529 IND-enabling studies should start shortly and NTX-819 is expected to complete IND-enabling studies in the coming months. The next milestone for the SUD program is the filing of an IND, and for the cough program, the start of IND-enabling studies, which are planned and ready to start subject to securing financing. Addex is also preparing dipraglurant for phase II in post-stroke recovery, and said it is looking forward to completing the evaluation of potential indications for its mGlu2 PAM program and securing the financial resources to advance its portfolio into clinical studies.
Addex Therapeutics Financial Statement Overview
Summary
Financial performance is critically weak. Revenue has collapsed by over 97% to just $63K, net profit margin is deeply negative at -108.7%, and the company is burning cash consistently. The sole positive is a debt-free balance sheet, but equity is rapidly eroding, indicating a high risk of insolvency without new funding.
Income Statement
8Very NegativeBalance Sheet
45NeutralCash Flow
10Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 63.19K | 173.00K | 410.04K | 1.61M | 1.42M | 2.92M |
| Gross Profit | 26.03K | 164.39K | -444.26K | -5.32M | -13.20M | -9.67M |
| EBITDA | -3.44M | -2.81M | -4.65M | -10.26M | -20.43M | -14.94M |
| Net Income | -6.87M | -6.73M | 7.06M | -10.56M | -20.80M | -15.41M |
Balance Sheet | ||||||
| Total Assets | 3.48M | 6.36M | 10.67M | 4.64M | 8.28M | 22.54M |
| Cash, Cash Equivalents and Short-Term Investments | 767.33K | 1.64M | 3.34M | 3.87M | 6.96M | 20.50M |
| Total Debt | 77.50K | 34.69K | 41.99K | 344.34K | 373.13K | 482.01K |
| Total Liabilities | 1.57M | 1.60M | 1.00M | 3.50M | 3.37M | 5.61M |
| Stockholders Equity | 1.90M | 4.76M | 9.67M | 1.15M | 4.91M | 16.93M |
Cash Flow | ||||||
| Free Cash Flow | -2.39M | -2.17M | -5.37M | -8.00M | -16.44M | -14.74M |
| Operating Cash Flow | -2.39M | -2.17M | -5.37M | -7.99M | -16.44M | -14.71M |
| Investing Cash Flow | 56.67K | -680.69K | 4.65M | -6,842 | 2,972 | -30.31K |
| Financing Cash Flow | 793.88K | 1.19M | 104.97K | 5.26M | 3.10M | 16.40M |
Addex Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:ADXN, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of 0.00 indicates Positive momentum. The RSI at 41.94 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:ADXN.
Addex Therapeutics Risk Analysis
Addex Therapeutics disclosed 54 risk factors in its most recent earnings report. Addex Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAddex Therapeutics Peers Comparison
Overall Rating
CH:ADXN41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 41Neutral | CHF 3.13M | -0.51 | -204.04% | ― | -50.34% | 4.75% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CH:ADXN | Addex Therapeutics Ltd | 0.02 | -0.03 | -56.60% |
Addex Therapeutics Corporate Events
Addex to Report Third-Quarter 2026 Results and Corporate Update
Addex Therapeutics is a clinical-stage biopharmaceutical company developing novel small-molecule allosteric modulators for neurological disorders, including dipraglurant for potential brain-injury recovery applications and GABAB PAM candidates for su...
Neurosterix Closes $105 Million Series B Financing
Addex Therapeutics, a clinical-stage biopharmaceutical company developing small-molecule allosteric modulators for neurological disorders, said its spin-out Neurosterix closed a $105 million Series B financing. Addex did not participate, and its equi...
Addex Boosts Issued Share Capital to Enhance Financing Flexibility
Addex Therapeutics has issued and fully subscribed 93 million new registered shares, each with a nominal value of CHF 0.01, through its wholly owned subsidiary Addex Pharma S.A., with the new shares listed on the SIX Swiss Exchange. The move raises t...
Addex Spin-Out Neurosterix Advances Schizophrenia Drug NTX-253 Into Phase 2
Addex Therapeutics reported that its spin-out Neurosterix has completed Phase 1 clinical studies of NTX-253, a positive allosteric modulator of the muscarinic M4 receptor being developed for schizophrenia, and plans to move the candidate into Phase 2...
Addex Therapeutics Brings Back Veteran Chemist to Lead Pharmaceutical Development as Pipeline Enters New Phase
Addex Therapeutics has appointed veteran medicinal chemist Jean‑Philippe Rocher as Head of Pharmaceutical Development and member of the executive team, while Mikhail Kalinichev steps down as Head of Translational Science to focus on his role at spin‑...
Addex Raises Fresh Funds as It Regains GABAB Rights and Advances CNS Pipeline
Addex Therapeutics reported its 2026 half-year results, highlighting a tighter financial position alongside strategic progress in its neurology-focused pipeline. The company’s cash and cash equivalents fell to CHF 0.8 million from CHF 2.3 million a y...
Addex Regains Global Rights to Key GABAB Assets, Expands Neurology Portfolio
Addex Therapeutics has regained full global rights to all GABAB positive allosteric modulator assets previously under collaboration with Indivior, following Indivior’s strategic refocus and planned merger with Supernus Pharmaceuticals, Inc. The move...
Addex to Present Half-Year Results and Pipeline Update
Addex Therapeutics, a clinical-stage biopharmaceutical group listed on SIX and Nasdaq under the ticker ADXN, focuses on small molecule allosteric modulators for neurological and psychiatric conditions and holds strategic interests in external program...
Addex Raises USD 2.8 Million, Extends Cash Runway to Late 2027
Addex Therapeutics, a clinical-stage biopharma focused on small molecule allosteric modulators for neurological diseases, is developing dipraglurant for brain injury recovery and advancing GABAB programs for substance use disorders and chronic cough,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
